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Abstract
What has been will be again, what has been done will be
done again; there is nothing new under the sun
(Ecclesiastes 1:9)
Stephen Paget was the conceptual father of the role
played by the Tumor Microenvironment (TME) in tumor
progression. The focus of this essay is the developmental
phase of the post Paget TME research. Attempts will be
made to highlight some of the pioneering work of scientists
from the late sixties through the eighties of last century who
laid the foundations for the contemporary scientific
achievements of TME research but whose ground breaking
studies are rarely cited. This review should serve as a small
tribute to their great work.
Keyword Tumormicroenvironment
The tumor microenvironment (TME) is a pivotal
factor in tumorigenesis and especially in tumor
progression and the pathogenesis of cancer is largely
dependent on its interactions with microenvironmental
components. This paradigm should be clear to every
cancer researcher, as it is for the participants of the
“5th International Conference on Tumor Microenvi-
ronment: Progression, Therapy & Prevention”.
This presentation attempts to highlight certain key events
of the developmental phase of the “tumor microenviron-
ment” concept which lead to the contemporary achieve-
ments of this research area. The essay which is not intended
to serve as a comprehensive review will conclude with a
biased view as to challenges facing TME researchers.
Stephen Paget laid the foundations of the TME research
area by formulating the seed and soil theory. Paget’s
concept lay dormant for many years. Only in the mid
seventies of the 20th century and onwards did a relatively
small group of people revisit Paget’s ideas [1–9]. Auerbach
[10], for example, cites Paget: “The best work in the
pathology of cancer is done by those studying the nature of
the seed. They are like scientific botanists; and he who
turns over the records of cases of cancer is only a
ploughman, but his observations of the properties of the
soil may also be useful”. Auerbach then expresses his own
views on cancer researchers who study the tumor microen-
vironment: “Those individuals who study the properties of
the host environment should not be ignored. Not only are
the observations of the ’soil’ useful, they provide essential
information without which we will not be able to
understand the nature of the metastatic process”.
From Infancy to Young Adulthood
The post Paget research of the TME was initiated by two
non-interacting groups of research pioneers: immunologists
and scientists focusing on angiogenesis. Until the late
seventies or early eighties, these two research groups
performed by far the most significant TME research.
Most of the early studies on the immune microenviron-
ment of cancer focused on the characterization and
functions of cellular and humoral immune components in
the tumor microenvironment [11–36] These studies estab-
lished that immunocytes including T cells [23, 32], B cells
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DOI 10.1007/s12307-009-0025-8[14, 17], NK cells [24, 31] and macrophages [19, 20, 26,
27, 29, 33, 35, 36] have the capacity to infiltrate solid
tumors in humans and in animals. Other studies demon-
strated that immunoglobulins (Ig) and complement compo-
nents could be detected in the microenvironment of solid
tumors. Tumor cells in humans, rats and mice were found
to be coated with Ig [11, 12, 18, 25, 34]. This coat was
composed either of anti tumor antibodies bound to the
tumor cells via the antigen binding site (in an antibody-
epitope interaction) [37] or of Ig (mainly IgG) bound to
epithelial or mesenchymal tumor cells via Fc receptors
(FcR) expressed by such tumor cells [38]. The tumor-
associated FcR was a promalignancy factor [39]. Micro-
environmental factors were found to regulate the expression
of the FcR expressed by the tumor cells [40].
The state of the art with respect to the immune
microenvironment of cancer was evaluated by leading
cancer immunologists in a UICC-supported workshop on
“In-Situ Expressions of Tumor Immunity” that took place
in 1978 in Tel Aviv, Israel. Some of the participants of the
1978 meeting participate also in the Versailles Conference.
The proceedings of the Tel Aviv meeting were published
[41]. Most of the presentations dealt with the characteriza-
tion of immune components (cells and molecules) found at
the sites of solid tumors and on their functional activities.
The bottom line of the workshop’s deliberations was that
the immune components that localized in the TME were
relatively deficient in anti tumor activities in comparison to
similar components originating from systemic sites. Some
tumor-localizing components, especially tumor-localizing
antibodies even enhanced tumor development.
The other group of TME pioneers led by Judah Folkman
focused on angiogenesis. They realized very early that tumor
proliferation was dependent upon blood supply and that the
interactions of tumor and endothelial cells initiated and drove
this process. Angiogenic factors were identified in various
types of tumors and the possibility was raised that inhibiting
such factors or their interaction with endothelial cells will be
of clinical benefit to cancer patients [42–59].
With the exception of research on the immune microen-
vironment and angiogenesis, the areas that today occupy
the forefront of TME research were essentially not
represented in the scientific arena until the early-mid
eighties. However, from there on, the research field of the
TME moved forward, expanding and enlarging its scope to
new frontiers.
Among the topics that were explored in the early eighties
were interactions between the extracellular matrix (ECM)
and tumor cells [60–64] and between fibroblasts and tumor
cells [65–67]. These and other studies published at that time
indicated that tumor-ECM or tumor-fibroblast interactions
may exert either anti tumor effects or the opposite, namely
pro malignancy effects.
Rudolph Virchow’s paradigm that inflammation contrib-
utes to carcinogenesis and tumor progression [68]h a s
developed into one of the major and most important aspects
of the TME area. It was demonstrated that inflammatory
cells (mainly macrophages) as well as proinflammatory
molecules such as cytokines and chemokines whose physi-
ologic function is to constitute a firewall against infectious
agents, are causally involved in the initiation of certain types
of cancer (inflammation-linked cancers) or in tumor progres-
sion of essentially all types of cancer [69, 70]. As mentioned
above, several studies from the seventies of last century
reported that mononuclear cells infiltrate solid tumors [19,
20, 26, 27, 29, 33, 35, 36]. It took several years to establish
that such cells are heavily involved in the pro malignancy
functions of cancer-linked inflammation [69–72].
However, many, if not most components of the TME
may, under certain circumstances, exert anti malignancy
activities whereas under different circumstances, they exert
pro malignancy effects [73]. Tumor infiltrating macro-
phages are no exception [74–78]. The contemporary studies
on tumor infiltrating macrophages tend, however, to stress
their pro malignancy effects rather than the anti malignancy
functions of these cells [71, 79–86].
Angiogenesis, the immune context of tumors, the
interrelationships of tumor cells with fibroblasts, compo-
nents of the ECM and pro-inflammatory mediators are
among the cutting edge topics of contemporary TME
research. It is important to realize that the pioneering
studies in these areas were undertaken at a time in which
cancer genetics dominated the scene.
The discoveries made in cancer genetics in the three
decade period from the early seventies until the end the
nineties are undoubtedly the golden era of this research
domain. The prevailing and dominating concept at that time
was that genetic alterations in oncogenes and tumor
suppressor genes are both necessary and sufficient to
initiate tumorigenesis and drive tumor progression.
What, if any was the relationship between cancer
geneticists and the “individuals who study the properties
of the host environment” (to use Auerbach’sw o r d s ) ?
Obviously both groups focused on different aspects of
malignancy, holding, most probably opposing views as to
the relative importance of cancer genes or of the TME to
the pathophysiology of cancer. There is no indication that a
direct or indirect debate between those groups took place.
Seemingly the concept that assigns to cancer genes the
primary role in carcinogenesis was in no conflict with the
concept attributing site specific metastasis to the outcome
of interactions between the seed (the tumor) and the soil
(the TME). None the less, armed with cutting edge and
sophisticated technologies the cancer geneticists established
themselves as strong and influential policy makers while
the microenvironmentalists, generating “uninteresting” data
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stream of cancer research at that time.
The nineties of last century marked a change in this
attitude. The contribution of the TME to cancer progression
started to be recognized by an increasing number of cancer
researchers.
A primary factor responsible for this development was the
revolution in biomedicine brought about by the identification
and functions of molecules involved in signal transduction
and the elucidation of signaling pathways [87–105].
Armed with novel knowledge and technologies it was
demonstrated that gene expression in tumor cells as well as
in non-tumor cells residing in the TME, is regulated by
microenvironmental factors [e.g., 106, 107]. Assessment of
the relative contribution of microenvironmental factors
versus genetic lesions to the shaping of the malignancy
phenotype of tumor cells indicated that the latter are not the
sole and exclusive driver of malignancy.
For example, it was demonstrated that oncogenes and a
microenvironmental factor (hypoxia) synergistically modu-
lated VEGF expression in tumor cells and impacted
angiogenesis [108]. Another study, performed in my lab,
showed that the microenvironment played an important role
in tumorigenesis. The tumorigenicity of polyoma virus-
transformed BALB/C 3T3 cells in syngeneic mice
depended on the microenvironment in which these cells
were grown rather than on the content of the polyoma
middle T oncogene [109].
Another important factor that helped to bring TME to the
fore front of cancer research was that notable scientists
from other domains of cancer research joined the ranks of
the tumor microenvironmetalists.
Mina Bissell, a noted developmental biologist was early
in realizing that similarly to the dependence of develop-
mental processes on the microenvironment, also tumor
progression is dependent upon the microenvironment [110].
In another article Bissell’s group wrote “Several lines of
evidence now support the contention that the pathogenesis
of breast cancer is determined (at least in part) by the
dynamic interplay between the ductal epithelial cells, the
microenvironment, and the tissue structure (acini). Thus, to
understand the mechanisms involved in carcinogenesis, the
role of the microenvironment (ECM as well as the stromal
cells) with respect to tissue structure should be considered
and studied” [111]. Bissell and her colleagues concluded:
“The current dominant paradigm wherein multiple genetic
lesions provide both the impetus for, and the Achilles heel
of, cancer might be inadequate to understand cancer as a
disease process” [112].
Holding a similar view, Ruth Sager, a leader in
cancer genetics wrote in one of her last articles before
her untimely departure that the oncogenes and tumor
suppressor genes known at that time, “affect principally
cell cycle regulation. None are known to affect invasion
or metastasis”. These genes “do not begin to account
for the diversity of cancer phenotypes” [113]. Sager
recommended shifting the focus from DNA to RNA i.e. to
expression genetics of cancer. She also advocated the
“grouping of cancer genes into two classes: class I genes
are mutated or deleted, whereas class II genes are not
altered at the DNA level. Rather they affect the phenotype
by expression changes”. Class 2 cancer genes are those
controlled by the microenvironment. A similar view was
expressed, 7 years later, by Vogelstein and Kinzler [114].
They indicated that the late stages of cancer are not
specifically associated with abnormalities in cancer genes
(i.e. oncogenes and tumor suppressor genes).
The multitude of microenvironmental factors, their
enormous activity spectrum and the complexity of their
intermolecular cross talk obviously requires an interactive
and interdisciplinary exchange between researchers en-
gaged in this research domain. A group of investigators
thought to promote such interactions at the international
level by organizing meetings dedicated exclusively to
TME. The first “International Conference on Tumor
Microenvironment: Progression, Therapy, Prevention”
was held in Israel on the shore of the Sea of Galilee in
1995. Among the 250 participants were several who
participate in the present conference. The Sea of Galilee
meeting was a truly multidisciplinary event where the focal
issue, the TME, was approached and discussed thoroughly
by specialists from a wide spectrum of biomedical
sciences.
The 1995 conference was the impetus to establish the
International Cancer Microenvironment Forum (ICMF).
The forum was founded by an international group of about
twenty cancer researches from ten countries. These scien-
tists who were joined a few years later by additional
scientists became the “charter member” group of ICMF.
Informal charter member meetings were held in London
(1997—hosted by Frances R. Balkwill, Imperial Cancer
Research Fund); Pittsburgh, (1999—hosted by Theresa L.
Whiteside and Ronald B. Herberman, University of
Pittsburgh Cancer Institute), San Sebastian, (2003—hosted
by Fernando Vidal-Vanaclocha, Basque Country University,
School of Medicine) and in Safed (2008—hosted by the
Israeli Charter Members). Present in these meetings were
charter members and some invited guests. These informal
meetings were devoted mainly to discussions on recent
results of studies connected with the TME.
One of the resolutions of the 2003 San Sebastian charter
member meeting was to upgrade ICMF. The International
Cancer Microenvironment Society (ICMS) was thus estab-
lished. The new society thrives to constitute a significant
driving force towards the development of novel,
microenvironment-related cancer therapy modalities.
The tumor microenvironment S11The second and the third “Tumor Microenvironment”
conferences were held in Baden, Austria (2002) and in
Prague, Czech Republic (2004). The fourth “Tumor
Microenvironment” conference was held in Florence, Italy
in 2007 in a joint venture with the American Association
for Cancer Research. All four meetings met, in full, the
intentions of the organizers to create a friendly forum that
promotes a critical review of novel basic findings and of
innovative clinical studies pertaining to the TME.
The scientific seeds planted in the TME field in the early
seventies of the twentieth century, bore fruit which ripened
about 10–15 years ago. The TME is increasingly recog-
nized by cancer researchers as a pivotal factor in tumor
progression and as a promising venue for drug discovery.
Indeed many of the novel cancer therapy modalities
interfere with tumor-microenvironment interactions. A
point in case is drugs that inhibit signals delivered to tumor
cells by microenvironmental growth factors via the
corresponding receptors [115–133].
The influx of highly capable and excellent scientists from
several domains ofbiosciences intothe TMEfieldcontributed
significantly to the increased popularity of this field and to its
becoming an innovative and stimulating research area.
The establishment also fulfilled its share in the accep-
tance of the TME as an important factor in cancer
development and progression.
Compelling examples for this are statements by a former
Director of NCI, Dr. Andrew C. von Eschenbach. In his
update from December 2, 2003, he wrote: “the cancer cell
is only part of the story in cancer development. Mounting
evidence now suggests that a cancer cell interacts with its
local and systemic microenvironments, and each profound-
ly influences the behavior of the other. These tumor-host
interactions permit, and even encourage, cancer progres-
sion. Two years ago, the National Cancer Institute
identified the tumor microenvironment as a priority
research area in an effort to expand our knowledge of
the cells and factors that normally populate the microen-
vironment as well as to advance our understanding of how
these microenvironment components interact with tumor
cells”.
Additional events that increased the impact of the TME
research area were:
& The launching by the National Cancer Institute, NIH, of
the Tumor Microenvironment Network initiative
(TMEN) with the funding of ten Programs (http://
tmen.nci.nih.gov/).
& The introduction of topics related to cancer microenvi-
ronment to the FP7-Health-2007 program of the
European Commission.
& The establishment of the TME Working Group by the
American Association for Cancer Research (http://www.
aacr.org/home/scientists/working-groups–task-forces/tu
mor-microenvironment-working-group.aspx).
& A huge increase in the number of publications dealing
with TME. Based on PubMed data, an increase of more
than eight fold occurred in the 14 year period from 1995
to 2008 (Fig. 1).
& A very large number of review articles on various
aspects of the TME that appeared recently. Only a small
minority out of scores of such articles is cited below
[73, 134–156].
& The inclusion of “Tumor Microenvironment” as a major
topic in leading international conferences.
& The recent founding of the official journal of the
International Cancer Microenvironment Society—“Cancer
Microenvironment” (http://www.springer.com/biomed/
cancer/journal/12307).
It is very difficult, if not impossible, to summarize, in a
single article, the state of the art with respect to each of the
interaction types between the tumor and its microenviron-
ment. Indeed it was not the aim of this article to do so.
None the less an attempt will be made to draw some general
hallmarks characterizing most instances of tumor-
microenvironment interactions.
Before doing so, it may be useful to point out the
conceptual differences between Paget’s perception of the
role of the microenvironment in tumor progression (Paget’s
focus was on site specific metastasis) and the modern
paradigm. Paget assigned to the microenvironment a role of
promoter/inhibitor of tumor cell proliferation at specific
secondary sites. According to his hypothesis the microen-
vironment at these sites either supports metastasis by
supplying growth promoting factors or alternatively inhibits
metastasis by growth inhibitors. On the other hand the



























Fig. 1 Number of TME-related publications during the period:
1995–2008
S12 I.P. Witzinductive, adaptive and selective function: The tumor is
directed into one or several possible molecular evolution
pathways by signals originating in native and/or modified
microenvironmental factors. Many of these pathways may
lead to metastasis.
The TME may be characterized as follows:
1. The molecular composition of the TME is established
jointly by tumor cells as well as by resident and
infiltrating non-tumor cells.
2. Interactions of cancer cells with components of their
microenvironment are crucial determinants in the
decision making process determining if cancer cells
will progress towards metastasis, if they will stay
dormant or if they will disappear altogether.
3. Tumor-microenvironment interactions are bidirectional.
Each of the interaction partners is capable of regulating
gene expression in the other partner, or of exerting
selective pressures on it. Each interaction partner thus
shapes the phenotype of the other partner.
4. Certain tumor-microenvironment interactions may ini-
tiate and drive circular chains of tumor progression–
enhancing events known as vicious cycles. In a typical
vicious cycle the tumor manipulates non-tumor cells in
the microenvironment and harnesses them to support its
progression.
5. Certain, possibly many, microenvironmental factors
play opposing roles in tumor progression by either
promoting or alternatively antagonizing this process.
Several variables such as the tumor type, the progres-
sion stage of the tumor, the status of certain receptors
on tumor cells determine if these factors will exert
either pro or anti malignancy activities.
6. Many tumor-microenvironment interactions promote
tumor progression.
Destinations
Alice: Would you tell me, please, which way I ought
to go from here?
The Cat: That depends a good deal on where you want to
get to
Alice: I don’t much care where
(Lewis Carroll—Alice in Wonderland)
The cancer research community, In contrast to Alice,
knows where it wants to get to: It thrives to cure cancer
and, hopefully prevent it.
Most of us would agree that the tumor has the capacity
to shape the phenotype of non tumor cells in the
microenvironment and to harness them to support its
progression. Accordingly the approaches to meet the goal
of cancer cure have undergone a significant change. Cancer
therapy has shifted from exclusively targeting only the
tumor to targeting three components: the tumor, its
accomplices and accessories in the microenvironment as
well as the interactions between them.
Numerous interactions between tumor cells and the
microenvironment have been identified. These interactions
may either restrain tumor progression or, more often,
promote it. Is any one of the pro-malignancy interactions
sufficient for metastasis or do tumor cells need all (or a
subgroup) of them in order to progress? Is there a hierarchy
of interactions that drive tumor progression? In other
words, are there more important and less important
interactions with respect to metastasis formation? Are we
able to identify those interactions that play the most
important roles in tumor progression and should be thus,
therapeutically targeted? Do different interactions integrate
through intertwined signaling cascades or through shared
molecules to a single interaction network?
It is up to the TME community to provide answers to
these questions which are obviously of enormous impor-
tance in the design of future cancer therapy drugs.
However, the immense multitude of candidate microenvir-
onmental factors, the extreme complexity of the signaling
cascades operating in the microenvironment, the intricacy
of the interactive crosstalk between these cascades, and
finally tumor heterogeneity, pose a formidable challenge
for those of us attempting to provide solutions to these
questions.
To overcome these challenges we need to provide a
comprehensive overall picture of the various molecular
cross-talks between tumor cells and their microenvironment
leadingtoanddrivingtumorprogression.Oneofthefirststeps
in our attempts to comprehend the big picture of tumor
progression is to realize that single molecules or single
signaling pathways are just solitary components of an
immense network. This realization should lead to the
abandonment of reductionism (which, I am afraid, is a
difficult mission under the present culture of conducting
science and its funding) and to the employment of approaches
used in Systems Biology [157–159].
In the interim tumor microenvironmentalists may con-
tribute to cancer therapy by:
1. Accumulating additional data on mechanisms of tumor-
microenvironment interactions
2. Finding ways to target those interactions with the
highest probability of influencing tumor progression
(expected are numerous opinions as to what these
interactions might be…)
3. Reversing the pro-malignancy effects of the microen-
vironment.
These goals are achievable.
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